• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, February 27, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

X-factor to help antibiotics regain their spark

Bioengineer by Bioengineer
February 23, 2021
in Immunology
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Holding off the rise of superbugs could be achieved by ‘resuscitating’ old antibiotics.

IMAGE

Credit: Institute for Molecular Bioscience, UQ

Holding off the rise of superbugs could be achieved by ‘resuscitating’ old antibiotics, with The University of Queensland researchers leading an international project to help combat the growing threat.

CARB-X, a global non-profit partnership funding the world’s largest antibacterial development pipeline, has funded the $AU2.9m project at UQ’s Institute for Molecular Bioscience (IMB).

Associate Professor Mark Blaskovich, Dr Alysha Elliott and Dr Johannes Zuegg will assess which antibiotics that are losing their effectiveness could be revived by combining them with a compound from a new family of antibiotics.

“We are running out of time to outsmart the most dangerous drug-resistant bacteria, the sort of infections that can cause deadly bacterial sepsis, pneumonia, urinary tract and wound infections,” Dr Blaskovich said.

“Compounds from a group known as the Octapeptins could be the spark the older drugs need to reinvigorate them as they act to disrupt the bacteria’s cell membrane–making it easier for the antibiotic to gain access.”

Dr Elliott said these ‘potentiators’ had been shown to help some antibiotics regain their activity against bacteria which have developed high levels of drug resistance, and reduce the amount of the antibiotic required to effectively kill bacteria by up to 100-fold.

“The benefit is that we can potentially restore the use of cheap generic antibiotics that are widely used in low and middle income countries, where there are high levels of drug-resistant bacteria,” Dr Elliott said.

“We will also share our expertise and technologies with researchers in countries such as Pakistan, Nepal, Egypt, Nigeria, Brazil, Thailand and Indonesia so they can genetically sequence resistant bacteria strains in real-time as they emerge.”

Dr Blaskovich said resistance to current antibiotics was increasing at an alarming rate, highlighting the urgent need for innovative solutions.

“With time of the essence, we are appreciative of the support of CARB-X to accelerate UQ’s IMB Centre for Superbug Solutions’ many-pronged attack on this global threat to human health,” Dr Blaskovich said.

###

The current project builds on the first Australian and first University CARB-X award to the Centre for Superbug Solutions in 2020 to develop the Octapeptin class as a stand-alone antibiotic treatment, led by Prof Matthew Cooper and Dr Karl Hansford along with Dr Blaskovich.

CARB-X receives its funding from the US Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust in the UK, Germany’s Federal Ministry of Education and Research (BMBF), the UK Global Antimicrobial Resistance (AMR) Innovation Fund (GAMRIF), and the Bill & Melinda Gates Foundation. Funding contributions by GAMRIF are earmarked by CARB-X to fund projects that focus on specific antibacterial priorities, and the UQ IMB Octapeptin LMIC project is one such project. GAMRIF funding allocated to CARB-X is focused on innovative research and development in the field of AMR, specifically in underinvested areas for LMICs, where the burden of AMR is greatest.

VIDEO:

https://youtu.be/DYYCGTa1gCY

Media Contact
Dr Jane Ilsley
[email protected]

Original Source

https://imb.uq.edu.au/article/2021/02/x-factor-help-antibiotics-regain-their-spark

Tags: BacteriologyDisease in the Developing WorldHealth CareInfectious/Emerging DiseasesMedicine/HealthMicrobiologyPublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Research reveals how bacteria defeat drugs that fight cystic fibrosis

February 26, 2021
IMAGE

Lethal house lures reduce incidence of malaria in children

February 26, 2021

Openly available toolkit to help lab-based coronavirus research

February 25, 2021

NIH awards UC San Diego $33 million for five COVID-19 diagnostic projects

February 25, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    638 shares
    Share 255 Tweet 160
  • People living with HIV face premature heart disease and barriers to care

    82 shares
    Share 33 Tweet 21
  • Global analysis suggests COVID-19 is seasonal

    38 shares
    Share 15 Tweet 10
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Technology/Engineering/Computer ScienceMedicine/HealthcancerInfectious/Emerging DiseasesEcology/EnvironmentMaterialsCell BiologyClimate ChangeBiologyGeneticsPublic HealthChemistry/Physics/Materials Sciences

Recent Posts

  • Predicts the onset of Alzheimer’s Disease (AD) using deep learning-based Splice-AI
  • When foams collapse (and when they don’t)
  • UTA researcher explores effects of trauma at the cellular, tissue levels of the brain
  • Picture books can boost physical activity for youth with autism
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In